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ABSTRACT
Humans have circulating antibodies against diverse glycans containing 
N-glycolylneuraminic acid (Neu5Gc) due to function-loss mutation of the CMAH 
gene. This xenogenic non-human carbohydrate is abundant in red meat, xenografts 
and biotherapeutics. Low levels of diet-derived Neu5Gc is also present on normal 
human endothelial cells, and together with anti-Neu5Gc antibodies could potentially 
mediate “xenosialitis” chronic-inflammation. Rabbit anti-human thymocyte 
globulin (ATG) is a drug containing polyclonal IgG glycoproteins commonly used 
as an immunosuppressant in human transplantation and autoimmune diseases. In 
type-1 diabetes patients, infusion of Neu5Gc-glycosylated ATG caused increased 
global anti-Neu5Gc response. Here, for the first time we explore changes in anti-
Neu5Gc IgG repertoire following the immunization elicited by ATG, compared with 
the basal antibodies repertoire that reflect exposure to dietary-Neu5Gc. We used 
glycan microarrays with multiple Neu5Gc-glycans and controls to elucidate eventual 
differences in ATG-elicited repertoire, before/after ATG administration and track 
their kinetics (0, 1, 18 and 24 months). Response of all basal-pre-existing Neu5Gc-
specific antibodies rapidly increased. This response peaked at one month post-ATG, 
with enhanced affinity, then resolved at 18–24 months. Induced-antibodies showed 
expanded diversity and de-novo recognition of different Neu5Gc-glycans, including 
endogenous glycolipids, that was further validated by affinity-purified anti-Neu5Gc 
antibodies from patients’ sera. These findings strongly suggest that ATG-induced anti-
Neu5Gc IgGs represent a secondary exposure to this dietary carbohydrate-antigen 
in humans, with immune memory. Given their modified recognition patterns, ATG-
evoked anti-Neu5Gc antibodies could potentially mediate biological effects different 
from pre-existing antibodies.
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INTRODUCTION
Humans develop a comprehensive immune response 
against Neu5Gc, a foreign dietary sialic acid form, with 
significant potential implications on chronic inflammation-
mediated  diseases such as cancer, atherosclerosis and 
xeno-transplantation [1-4]. Human anti-Neu5Gc antibodies 
behave differently from many other anti-carbohydrate 
antibodies [5]. These xeno-autoantibodies appear in 
infants coinciding with exposure to dietary Neu5Gc [6], 
are enhanced during disease [7, 8], class switched  switch 
from IgM to IgG/IgA [9, 10]. Despite variable recognition 
profiles between human sera [9, 11], the levels can 
remain high for many years within the same individual 
[10]. Unlike other mammals, humans cannot hydroxylate 
cytidine 5’-monophosphate-N-acetylneuraminic acid 
(CMP-Neu5Ac) to synthesize Neu5Gc due to a specific 
gene loss-mutation. Instead, humans get exposed to 
Neu5Gc through dietary consumption of mammalian 
meat and dairy [1-4], and through biomedical exposure 
to Neu5Gc-glycosylated animal-derived tissues [2], 
biotherapeutics or bio-devices that are commonly used 
in the clinic [4, 12]. While humans cannot synthesize 
Neu5Gc, dietary-Neu5Gc can nevertheless be absorbed 
by human cells with subsequent low level expression on 
the surface of endothelial cells and some epithelial cells 
generating xeno-auto-antigens [1]. The combination of 
circulating anti-Neu5Gc antibodies with accumulated 
Neu5Gc on human cells leads to a unique situation of 
chronic inflammation defined as ‘xenosialitis’ [13, 14], that 
had been suggested to exacerbate various human diseases 
[3]. Experimental xenoxialitis had been demonstrated in 
mice [13, 14], yet in humans it may be even more complex 
and could likely be affected by changes in anti-Neu5Gc 
repertoire, for example by antibodies elicited through a 
non-dietary route. Therefore, deciphering the nature and 
repertoire of bioterapeutic-elicited anti-Neu5Gc antibodies 
could be critical for understanding their possible role in 
the immunopathogenesis of related chronic-inflammation 
mediated diseases. Neu5Gc and Neu5Ac, that differ by 
a single oxygen, are the two major sialic acids forms in 
mammals, which are ubiquitously expressed at the tip of 
diverse carbohydrate chains (glycans) on glycoproteins 
and glycolipids [1, 15-17]. It is challenging to measure 
anti-Neu5Gc antibodies, because they recognize multiple 
Neu5Gc-glycan epitopes, on a large collection of Neu5Gc-
containing sugar chains. This variety results from 
Neu5Gc attachment to diverse underlying sugar-chains, 
with different linkages, glycan conjugation to protein/
lipid-carriers and their diverse cell-surface density. To 
estimate overall anti-Neu5Gc response, a simple ELISA 
Inhibition Assay (EIA [7]) has been developed based on 
reactivity against multiple mouse Neu5Gc-containing 
glycoproteins, yet detailed information can only be 
achieved by measuring responses to distinct Neu5Gc-
glycans with Neu5Ac-glycans counterparts serving as 
controls, facilitated by large scale analysis using printed 
arrays [9, 18, 19]. 
Rabbit anti-thymocyte globulin (ATG) is a 
polyclonal IgG preparation used for induction treatment 
of immunosuppression during various types of solid 
organ allografts, allogeneic stem cell transplants and 
autoimmune diseases [20]. These rabbit glycosylated 
antibodies carry determinants foreign to humans, including 
Neu5Gc-xenoantigens [4]. ATG therapy was administered 
to patients with new onset type-1 diabetes without 
additional immunosuppression in the START (Study 
of Thymoglobulin to ARrest Type 1 diabetes ) study, a 
phase II clinical trial (ClinicalTrials.gov #NCT00515099) 
that aimed to evaluate its effect on preservation of β-cell 
function [21, 22]. In these patients, ELISA-EIA analysis 
revealed a significant increase of both global anti-Neu5Gc 
IgM and IgG after ATG treatment [23]. Here, we use 
glycan microarray to profile the kinetics, specificity, 
affinity and repertoire diversity of anti-Neu5Gc IgGs 
following ATG treatment. The top seven EIA-responders 
were analyzed over a large panel of Neu5Gc-glycans 
and Neu5Ac-glycans on microarrays. This revealed that 
the drug-induced anti-Neu5Gc response is dramatically 
different from the basal response, with a strong induction 
of all pre-existing anti-Neu5Gc IgGs, as well as newly 
developed IgG repertoires against diverse Neu5Gc-
glycans, with increased binding-affinity. 
RESULTS
To investigate carbohydrate immune recognition in 
the context of anti-Neu5Gc response, we took advantage 
of the availability of serum samples from the seven 
START study participants [21, 22] that had the highest 
titers of anti-Neu5Gc IgG one month following the four-
days course of rabbit ATG treatment (Thymoglobulin-
Genzyme; day 1: 0.5 mg/kg, days 2-4: 2 mg/kg; without 
additional immunosuppressive agents) [23], as determined 
by EIA [7] (Table 1). ATG targets multiple T-cell antigens, 
and its immunosuppressive activity is largely associated 
to peripheral T cell depletion, however it also affects other 
cell types [20, 24]. 
For detailed profiling of anti-Neu5Gc immune 
responses we used a unique sialoglycan microarray with 
various Neu5Gc-glycans and control Neu5Ac-glycans, 
each covalently attached to epoxy-activated glass slides 
[7]. We focused on IgG response that had been suggested 
to mediate chronic inflammation diseases, and for this 
purpose used anti-human IgG specific secondary antibody 
that had been validated to lack cross reactivity with other 
human Ig isotypes (i.e. IgM, IgA). To characterize the 
kinetics of response to these diverse glycans we analyzed 
patients’ serum samples obtained before-ATG [screening 
visit (-1), day of treatment (0; before administration)], and 
samples taken after treatment (at 1, 18 and 24 months). In 
all patients, there was a clear induction of highly-specific 
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anti-Neu5Gc IgG response, with minimal/no recognition 
of control Neu5Ac-glycans (Figure 1), confirming previous 
EIA analysis [23]. Anti-Neu5Gc responses were increased 
vigorously, peaking at one month post-ATG infusion, 
then resolved at 18-24 months (Figure 1, Supplementary 
Figure 1). This exemplifies a long-term effect despite a 
short initial antigenic challenge, supporting previous 
studies in patients shortly exposed to animal-derived 
tissues [10]. At one month, all pre-ATG-M0 antibodies 
were elevated, and in addition, antibodies to new epitopes 
were detected in sera of most subjects, showing that ATG-
treatment increased the repertoire diversity by eliciting de 
novo recognition of individual Neu5Gc-glycans (Figure 
1A, Supplementary Figure 1B; for example, glycan ID 
#73 in S1-S3, and glycan IDs #72, #73, #69, #67, #75 in 
S5). The most prominent examples of this were observed 
for S4/S5-microarrays (Figure 2A-2B). These newly 
generated anti-Neu5Gc IgGs were not detected prior to 
ATG treatment at month 0, and recognized several mono-
sialylated α2-3/6-linked glycans and the glycosphingolipid 
oligosaccharide α2-8-linked Neu5Gc-di-sialylated 
glycan (ID#75: Neu5Gcα8Neu5Gcα3Galβ4GlcβO-
Linker; Figure 2B). Importantly, this glycolipid-glycan 
recognition was highly specific with low cross-reactivity 
to other Neu5Gc-glycans, as demonstrated by differential 
reactivity-inhibition with glycan ID#75 (Figure 3A). 
Glycolipid recognition was unexpected since ATG-IgGs 
are glycoproteins containing N-glycans that lack Siaα2-8, 
as determined by mass-spectrometry [4]. Lectin analysis 
showed ATG-IgGs carry both Siaα2-3 and Siaα2-6, with 
HPLC-quantified Neu5Gc (3.1 ± 0.05 pmole/μg ATG) at 
~7-fold over Neu5Ac (Supplementary Figure 2). At one 
month, the average total anti-Neu5Gc IgG response was 
dramatically enhanced in S4 by 7-fold and in S5 by 122-
fold (S4: 343 ± 131 to 2495 ± 251; S5: 142 ± 52 to 17338 
± 2157; RFU mean ± SE) (Figure 2B). In both S4 and S5, 
de novo induced anti-Neu5Gc IgGs peaked at one month 
post-ATG (M1), but only in S5 remained in circulation 
through 18-24 months (Figure 1), suggesting differences 
in the quality of the humoral response elicited by ATG 
in different individuals, and also that introduction of 
these animal-derived Neu5Gc-containing glycoproteins 
sometimes result in a long-lasting antibody exposure to 
new Neu5Gc-epitopes.
To directly compare the quality of pre-existing 
versus ATG-induced anti-Neu5Gc antibodies from these 
patients’ sera, anti-Neu5Gc IgGs were affinity-purified. 
Sera were loaded on two sequential columns with the 
first containing Neu5Ac-glycoproteins, and the second 
containing Neu5Gc-glycoproteins, from which anti-
Neu5Gc antibodies were eluted with free Neu5Gc [9]. 
Due to expected low quantities of anti-Neu5Gc antibodies 
in pre-ATG sera (Figure 1), serum from all seven patients 
collected before ATG-treatment were pooled together 
for affinity-purification, yielding 3.2 μg/ml pooled 
sera (total 10 ml). At the one month time point, anti-
Table 1: Patients characteristics
 Treatment
 (n = 7)
Age in years 20 (7.8)
    12–21 years 3 (43%)
    22–35 years 4 (57%)
Men 4 (57%)
Ethnic origin
    White 6 (86%)
    Non-white 1 (14%)
Body-mass index 22.4 (2.2)
Days since diagnosis 62.7 (24.4)
Baseline 2-h C-peptide area under the curve (pmol/ml) 0.764 (0.219)
Anti-Neu5Gc IgG (ng/μ
l)* 
    Baseline 5.4 (2.3)
    Month 1 212.4 (368.9)
* Measure by EIA assay [7].
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Neu5Gc antibodies were affinity-purified from individual 
sera, resulting in 30.8 ± 13.7 μg/ml sera (mean ± SE), 
demonstrating at least 10-14-fold more antibodies in the 
elicited response. These yields likely represent most anti-
Neu5Gc reactivity due to minimal residual-reactivity 
in the column flow-through after purification (data not 
shown). Glycan microarray analysis of these purified 
anti-Neu5Gc antibodies confirmed their high specificity 
towards all Neu5Gc-glycans, and not towards Neu5Ac-
glycans (Figure 3B). These elevated antibody quantity 
yields at M1 compared to pooled pre-ATG levels were 
also associated with a major enhancement in reactivity, as 
exemplified in S4/S5 (Figure 2B). 
To test whether the increased reactivity against 
various Neu5Gc-epitopes was also associated with 
enhanced binding strength, we evaluated the affinity 
equilibrium constant K
D
. Due to limited sample 
availability, K
D
 could not be determined from kinetic 
measurements (the ratio of the rate constants kd/ka). 
Instead it was estimated through glycan microarray 
analysis, by fitting a plot of response at equilibrium 
against a wide range of purified anti-Neu5Gc antibody 
concentrations, with a constant concentration of each 
of the printed Neu5Gc-glycans (at 100 μM). This array-
titration analysis of purified-antibodies suggest a ~7-
fold increased IgG-affinity at S5-M1 versus pre-ATG 
(0.2-22.1-fold K
D
 increase against individual Neu5Gc-
glycans; Figure 3C, Supplementary Table 2). To further 
evaluate the efficiency of affinity-purification to obtain the 
authentic pool of induced antibodies from each serum, we 
analyzed profiles of average Neu5Gc-glycans responses 
against specific Sia-linkages (Siaα2-3/6/8; Figure 3D). 
This confirmed the expanded repertoire diversity in 
elicited anti-Neu5Gc antibodies post-ATG. Furthermore, 
the affinity-purified antibodies maintained their unique 
serum-repertoire patterns, and their differences from 
Figure 1: Diverse anti-Neu5Gc IgG response is induced after ATG treatment. A. Sequential sera samples pre-/post-ATG 
therapy were tested at 1:100 dilution on sialoglycan microarrays, then detected by Cy3-anti-human IgG (40 ng/well). Relative fluorescence 
units (RFU) of all mono-sialylated Neu5Ac-glycans or Neu5Gc-glycans showed induction of highly specific anti-Neu5Gc response that 
peaked at one month post-ATG with some Neu5Gc-glycans responses sustained at 18-24 months post-ATG (Heatmap across all samples: 
red-white-blue represent maximum – 50th percentile – minimum reactivity, respectively; minimum and maximum values are indicated in the 
figure; repeated measures One-Way ANOVA, *** P < 0.0001 significant between M0 and M1; detailed analysis described in Supplementary 
Figure 1A). Glycan structures are detailed in Supplementary Table 1. B. Average RFU of all mono-sialylated Neu5Ac-glycans (blue line) or 
Neu5Gc-glycans (red line) showed induction of highly specific anti-Neu5Gc response peaking one month post-ATG.
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other samples (Figure 3D). Likewise, correlation patterns 
between sera before/after purification remained the same 
(Figure 3E). Altogether, these data provide direct evidence 
that the short treatment with Neu5Gc-glycosylated foreign 
ATG not only causes a quantitative induction, but also a 
qualitative enhancement of highly specific anti-Neu5Gc 
IgGs, with improved affinities. Importantly, this highly-
specific and diverse induced response is not limited to 
Neu5Gc-antigens on ATG-protein-carriers, but can also 
recognize Neu5Gc-glycolipids, implying a recall response 
with activation of initially-quiescent memory. 
DISCUSSION
Antibody secretion is initiated by activated-B cells 
that differentiate into short- or long-lived plasma cells. 
To diversify the repertoire of antigen-specific cells and 
optimize their affinity, activated-B cells transiently repress 
plasma cell (PC) differentiation followed by class-switch 
recombination (e.g. to IgG), or that they enter the germinal 
center (GC) for somatic hypermutation and class-switch 
recombination to yield high-affinity clonal variants that 
differentiate into either quiescent memory-B cells or 
plasma cells [25]. Some GC-plasma cells turn into long-
lived plasma cells (LLPCs) in the bone marrow, where 
they do not proliferate, but act as long-term antibody 
factories [25, 26]. 
The enhanced and diverse anti-Neu5Gc immune 
response following Neu5Gc-ATG treatment is thus likely 
mediated by memory-B cells, that could include both 
quiescent memory-B cells and LLPCs. At one month, the 
dramatic increase in pre-existing anti-Neu5Gc IgGs is in 
contrast to the overall transient B cell depletion observed 
in these patients [21]. Furthermore, the increase in anti-
Neu5Gc IgGs repertoire-breadth, with de novo recognition 
patterns, supports the anamnestic involvement of quiescent 
memory-B cells that become activated upon re-exposure 
to Neu5Gc-glycosylated-ATG. This is further corroborated 
by the recognition of Neu5Gc-glycolipid glycans not 
expected to appear on ATG-glycoproteins. 
This study was limited to antibody repertoires in 
patients’ serum samples, lacking accessibility to blood 
cells in ‘real time’, yet the elaborated results strongly 
substantiate the existence of memory responses to the 
Neu5Gc-dietary carbohydrate antigen. Circulating anti-
Neu5Gc antibodies may contribute to exacerbation of 
chronic inflammation-mediated diseases [8, 27], including 
in cancer and vascular lesions [14, 28-31], but are also 
potential therapeutics or biomarkers [1, 3, 32]. Our 
findings provide the first description of the drug-elicited 
anti-Neu5Gc IgGs with different repertoires and affinities. 
These may contribute to as yet unidentified pathologies in 
patients exposed to high levels of such elicited-antibodies 
for long periods after stimulation with animal-derived 
Figure 2: Diverse de novo anti-Neu5Gc IgGs repertoire post-ATG. A. Pie charts of anti-Neu5Gc IgG microarray recognition 
patterns against each Neu5Gc-glycan in S4 and S5 pre-ATG (M0) and post-ATG (M1) exemplifies increased diversity (each pie faction 
represents a different Neu5Gc-glycan, demonstrating increased number of Neu5Gc-glycans that are being recognized at M1 compared with 
M0 in each sera, reflected by increased number of pie fractions in M1). B. S4 and S5 RFU divided to common underlying core-glycan-
structures demonstrate de novo recognition of additional Neu5Gc-glycans with strongly increased intensities.
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molecules or tissues [4, 12]. Drug-induced anti-Neu5Gc 
antibodies could potentially recognize integrated dietary-
Neu5Gc on endothelial/epithelial cells [1, 3], and interfere 
with their proper functions. In this respect, our findings 
suggest that further investigation of induced anti-Neu5Gc 
antibodies is warranted, especially those being elicited 
in patients challenged with animal-derived drugs, grafts, 
tissues or bioprosthetic devices.
MATERIALS AND METHODS
Human sera samples
Seven patients’ sera were obtained from the START 
study (Gitelman et al., 2013) (Table 1) and used in 
accordance with the Helsinki declaration and Tel Aviv 
University Institutional Review Board. 
Antibodies
Neu5Gc IgY (Biolegend), biotinylated-SNA and 
biotinylated-MAL-II (Vector Labs), HRP-donkey-anti-
chicken IgY, HRP-Streptavidin and Cy3-goat-anti-human-
IgG (H+L) (Jackson ImmunoResearch).
Affinity purification of anti-Neu5Gc antibodies 
from human sera
Antibodies were purified as previously described 
[9]. The sera of all seven patients at M(-1) and M0 were 
Figure 3: Characterization of affinity-purified anti-Neu5Gc IgGs pre- and post-ATG. A. Anti-Neu5Gc antibodies were 
affinity-purified from pooled pre-ATG or S5-M1 sera then 1 μg/well each analyzed by sialoglycan microarrays, in the presence or absence 
of 0.5 mM of competing glycan ID#75 (Neu5Gcα8Neu5Gcα3Galβ4GlcβO-Linker), followed by detection with Cy3-anti-human IgG (40 
ng/well). Reactivity against glycolipid-glycans (α8) is greatly inhibited compared to others (α3/6) (One-way AVONA, Bonferroni post-
test, p = 0.0012). B. Affinity-purified antibodies tested at 1 μg/well followed by Cy3-anti-human IgG confirmed high Neu5Gc-specificity 
(Heatmap across all samples). C. To evaluate affinities of purified anti-Neu5Gc antibodies from pre-ATG versus S5-M1 sera, IgGs reactivity 
was tested at 14 quartile-serial dilutions and K
D
-values/glycan calculated, demonstrating increased affinities post-ATG (medians; non-linear 
fit with one-site specific binding; Table S2). D. Pie charts of anti-Neu5Gc-IgG divided by Sia-linkages reveals increased diversity pre-/
post-ATG, that is maintained after affinity-purification. Charts represent average response against Neu5Gc-glycans with Siaα2–3 linkage 
(α3), Siaα2–6 linkage (α6), glycolipid-type di/tri-sialylated with Siaα2–8 linkage (α8), or the branched di-Sia (α3/6). E. Similar correlation 
of anti-Neu5Gc IgG at M1-post-ATG before/after affinity-purification between patients (Pearson, Two-tailed, 95% CI), supporting efficient 
affinity-purification.
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pooled resulting in 32.3 μg of the pooled 10 ml. Yields 
of sera at the peak response (M1) were 73.8 μg/ml S1-S2 
(221.4 μg of 3 ml pooled S1 and S2), 73.3 μg/ml S3 (183.1 
μg of 2.5 ml), 6.7 μg/ml S4 (13.4 μg of 2 ml), 18.4 μg/ml 
S5 (36.8 μg of 2 ml), 7.5 μg/ml S6 (1.87 μg of 0.25 ml), 
and 4.9 μg/ml S7 (9.8 μg of 2 ml).
Sialoglycan microarray fabrication
Arrays were fabricated with NanoPrint LM-60 
Microarray Printer (Arrayit) on epoxide-derivatized 
slides (Corning 40044), at 70% humidity, with four SMP3 
pins (Arrayit) at sixteen 20×20 sub-arrays on each slide 
(Version 2.0). Each glycoconjugate printed in 100 µM 
of optimized print buffer (300 mM phosphate buffer, pH 
8.4). Next, slides were packed, vacuum-sealed and stored 
at room temperature (RT) until used. 
Sialoglycan microarray binding assay
Slides were developed and analyzed as previously 
described [7] with some modifications. Slides were 
rehydrated with ddH
2
O and incubated for 30 min in a 
staining dish with 50 °C pre-warmed ethanolamine (0.05 
M) in Tris-HCl (0.1 M, pH 9.0) to block the remaining 
reactive epoxy groups on the slide surface, then washed 
with 50 °C pre-warmed ddH
2
O. Slides were centrifuged 
at 200 × g for three min then fitted with ProPlate™ Multi-
Array 16-well slide module (Invitrogen) to divide into the 
sub-arrays (blocks). Slides were washed with PBST (0.1 
% Tween 20), aspirated and blocked with 200 μl/sub-array 
of blocking buffer (PBS/OVA, 1% w/v ovalbumin, in PBS, 
pH 7.3) for 1 hour at RT with gentle shaking. Next, the 
blocking solution was aspirated and 100 μl/block of 1:100 
diluted sera or purified anti-Neu5Gc antibodies in 10 ng/
μl diluted in PBS/OVA were incubated with gentle shaking 
for 2 hours at RT. Slides were washed three times with 
PBST, then with PBS for 2 min. Bound antibodies were 
detected by incubating with secondary detection diluted in 
PBS, 200 μl/block at RT for 1 hour, Cy3-anti human IgG 
1.2 μg/ml (Jackson Immunoresearch). Slides were washed 
three times with PBST then with PBS for 10 min followed 
by removal from ProPlate™ Multi-Array slide module and 
immediately dipping in a staining dish with ddH
2
O for 10 
min with shaking, then centrifuged at 200 × g for 3 min 
and scanned immediately.
Array slide processing
Processed slides were scanned and analyzed as 
described at 10 μm resolution with a Genepix 4000B 
microarray scanner (Molecular Devices) at 350 gain. 
Image analysis was carried out with Genepix Pro 6.0 
analysis software (Molecular Devices). Spots were defined 
as circular features with a variable radius using with local 
background subtraction.
Affinity equilibrium constant KD calculation by 
microarray
Slides were developed as described above with 
serial quarterly dilutions of purified S5-M1 or purified 
pooled Pre-ATG antibodies at 10 ng/μl − 1.49 × 10-7 ng/
μl (66.6 nM − 9.93 × 10-7 nM) in PBS/OVA blocking 
buffer. K
D
 was calculated by fitting a plot of response at 
equilibrium against a wide range of purified anti-Neu5Gc 
antibody concentrations (12-13 dilutions, from 9.93 × 10-7 
nM up to 4.16 nM or 16.6 nM, in S5-M1 and pooled Pre-
ATG, respectively; non-linear fit with one-site specific 
binding, GraphPad Prism 6.0).
Selective inhibition with glycan ID #75 by 
microarray
Slides were developed as described with the 
following modifications. Purified 10 ng/μl of S5-M1 
were pre-incubated in the presence or absence of 0.5 mM 
glycan ID #75 in PBS/OVA blocking buffer for 2 hours on 
ice prior to loading on the slide for development.
Sialic acid detection by ELISA
Sialic acids were detected on ATG by ELISA as 
previously described [9]. ATG was coated in duplicates at 
1μg/well in 50 mM sodium carbonate-bicarbonate buffer, 
pH 9.5 onto 96-well microtiter plates (Costar, Corning) 
and plates were incubated overnight at 4 °C. Wells were 
blocked for 1 hour at room temperature with blocking 
buffer (PBS pH 7.4, 1% ovalbumin), then aspirated and 
incubated with diluted primary antibody 100 μl/well in the 
same blocking buffer for two hours at room temperature 
(chicken anti-Neu5Gc IgY at 1:7000, biotinylated SNA 
or MAL-II at 1 μg/ml). The plates were washed three 
times with PBST (PBS pH 7.4, 0.1% Tween-20) and 
subsequently incubated for 1 hour at RT with HRP-
conjugated secondary antibody in PBS (HRP-donkey-anti-
chicken IgY 0.26 μg/ml and HRP-streptavidin 0.09 μg/ml, 
respectively). After washing three times with PBST, wells 
were developed with 140 μl of O-phenylenediamine in 100 
mM citrate-PO
4
 buffer, pH 5.5, and the reaction stopped 




 (4 M). Absorbance was measured at 
490 nm on SpectraMax M3 (Molecular Devices). Specific 
binding was defined by subtracting the background 
readings obtained with the secondary antibody only on 
coated wells.
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Sialic acid analysis by DMB-HPLC
Sia content in ATG was analyzed as previously 
described [33]. Sias were released from glycoconjugates 




 for 1.5 hours 
at 80 °C, then neutralized with 0.1 M of NaOH. 
Free Sias were then derivatized with 1, 2-diamino-4, 
5-methylenedioxybenzene (DMB; Sigma) for 2.5 hours at 
50 °C, separated by Microcon-10 centrifugal filters and 
analyzed by fluorescence detection on reverse-phase high 
pressure liquid chromatography (DMB-HPLC; Hitachi 
HPLC Chromaster). HPLC run was on C18 column 
(Phenomenex C18 Gemini 250 × 4.6 mm) at 24 °C in 
running buffer [84.5% ddH
2
O, 8.5% acetonitrile, 7% 
methanol (Merck)] for 60 minutes (min) at a flow rate of 
0.9 ml/min. Quantification of Sias was done in comparison 
with known quantities of DMB-derivatized Neu5Ac.
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism 5.0 or 6.0, and described in context in the figure 
legends. P-value less than 0.05 was considered statistically 
significant.
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